News | August 11, 2024
Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Subscribe To Our Newsletter & Stay Updated
